Physician profile
Mitchell Kuppinger
NPI 1174517809
$1,123.04
in general payments reported to CMS, 2019-2025
20 companies · $488 in 2025
The $488 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.17 · 2021: $38.33 · 2022: $110 · 2023: $130 · 2024: $329 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $946.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $265.57 | 2024-2025 | Inspire |
| Harmony Biosciences LLC | $116.39 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $97.04 | 2019-2025 | Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $92.44 | 2023-2025 | Trelegy Ellipta, Nucala |
| Jazz Pharmaceuticals INC. | $74.24 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $59.21 | 2025 | Dupixent |
| Zoll Respicardia, INC. | $57.58 | 2023 | Remede System |
| Philips North America LLC | $55.17 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.79 | 2025 | |
| Ani Pharmaceuticals, INC. | $49.19 | 2025 | Purified Cortrophin Gel |
| Insmed, INC. | $40.70 | 2025 | Arikayce |
| Fisher & Paykel Healthcare INC | $31.58 | 2024 | Fisher & Paykel Healthcare |
| Vifor Pharma, INC. | $27.30 | 2025 | Zemaira |
| Merck Sharp & Dohme LLC | $22.50 | 2025 | Winrevair |
| Resmed Corp | $20.34 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19.88 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $15.14 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.60 | 2025 | Glassia |
| Mylan Specialty L.P. | $14.38 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Kuppinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.